Gelteq (GELS) Competitors $1.22 -0.06 (-4.69%) As of 10/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GELS vs. KPTI, LTRN, SNTI, ZIVO, TPST, CALC, ATNM, PDSB, ESLA, and NBRVShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), Senti Biosciences (SNTI), ZIVO Bioscience (ZIVO), Tempest Therapeutics (TPST), CalciMedica (CALC), Actinium Pharmaceuticals (ATNM), PDS Biotechnology (PDSB), Estrella Immunopharma (ESLA), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Karyopharm Therapeutics Lantern Pharma Senti Biosciences ZIVO Bioscience Tempest Therapeutics CalciMedica Actinium Pharmaceuticals PDS Biotechnology Estrella Immunopharma Nabriva Therapeutics Gelteq (NASDAQ:GELS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations. Do analysts recommend GELS or KPTI? Karyopharm Therapeutics has a consensus target price of $18.20, indicating a potential upside of 206.91%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals believe in GELS or KPTI? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GELS or KPTI more profitable? Gelteq has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Karyopharm Therapeutics -90.02%N/A -84.28% Does the media favor GELS or KPTI? In the previous week, Karyopharm Therapeutics had 18 more articles in the media than Gelteq. MarketBeat recorded 19 mentions for Karyopharm Therapeutics and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.00 beat Karyopharm Therapeutics' score of 0.44 indicating that Gelteq is being referred to more favorably in the media. Company Overall Sentiment Gelteq Positive Karyopharm Therapeutics Neutral Which has better earnings and valuation, GELS or KPTI? Gelteq has higher earnings, but lower revenue than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteq$100K115.17-$2.33MN/AN/AKaryopharm Therapeutics$145.24M0.35-$76.42M-$14.59-0.41 SummaryKaryopharm Therapeutics beats Gelteq on 7 of the 12 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.08M$3.40B$6.10B$10.50BDividend YieldN/A2.29%5.73%4.81%P/E RatioN/A22.4484.5227.09Price / Sales115.17427.40585.94210.58Price / CashN/A46.5937.1661.22Price / Book0.9410.4112.246.52Net Income-$2.33M-$52.47M$3.32B$276.75M7 Day Performance-6.15%2.32%1.25%2.00%1 Month Performance-16.44%11.14%6.28%2.26%1 Year PerformanceN/A11.15%59.92%35.58% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.22-4.7%N/AN/A$12.08M$100K0.00N/APositive NewsShort Interest ↓KPTIKaryopharm Therapeutics4.2098 of 5 stars$5.82-1.4%$20.60+254.0%-53.7%$51.16M$137.27M-0.40380Analyst RevisionHigh Trading VolumeLTRNLantern Pharma1.7457 of 5 stars$4.62+0.7%$25.00+441.1%+17.1%$49.90MN/A-2.6020News CoverageSNTISenti Biosciences3.3628 of 5 stars$1.90+6.7%$8.50+347.4%+0.0%$49.70MN/A-0.214Trending NewsAnalyst ForecastAnalyst RevisionZIVOZIVO Bioscience0.5587 of 5 stars$13.01+8.4%N/A-36.5%$49.66M$15.85K-2.6710News CoverageGap DownTPSTTempest Therapeutics1.4316 of 5 stars$10.78-1.8%$30.00+178.3%-32.2%$47.86MN/A-0.7420CALCCalciMedica3.2232 of 5 stars$3.38+6.0%$16.00+373.4%-18.9%$47.22MN/A-2.1130ATNMActinium Pharmaceuticals2.2168 of 5 stars$1.50-2.6%$4.50+200.0%-15.1%$46.79MN/A-1.0830PDSBPDS Biotechnology1.2288 of 5 stars$0.99-1.4%$10.00+914.3%-70.1%$46.37MN/A-1.0720ESLAEstrella Immunopharma2.8588 of 5 stars$1.23-5.4%$16.00+1,200.8%+108.3%$45.60MN/A-4.73N/APositive NewsShort Interest ↓Gap DownHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies Karyopharm Therapeutics Competitors Lantern Pharma Competitors Senti Biosciences Competitors ZIVO Bioscience Competitors Tempest Therapeutics Competitors CalciMedica Competitors Actinium Pharmaceuticals Competitors PDS Biotechnology Competitors Estrella Immunopharma Competitors Nabriva Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe Truth about AI Stocks’ Money MachineBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
